Lung Cancer
Conference Coverage
Lung cancer in 2030: Expand genotyping
Improve the ability to treat patients based on risk level and expand the use of targeted therapies.
Conference Coverage
Weighing the complexity of pathological response in lung cancer
Future work should aim to standardize pathology assessment.
Conference Coverage
Pembro provides DFS benefit in early NSCLC
But more data are needed to understand the longer-term survival outcomes and the role of PD-L1 as a predictive marker for sensitivity to immune...
Conference Coverage
Adding immunotherapy to chemo in lung cancer improves patient outcomes, new data show
Patient-reported outcomes are often released well after efficacy data, making treatment decisions more challenging.
From the Journals
Obesity increasing the risk for cancer: It’s complicated
For some cancers it was “very clear that obesity increased the risk ... but for some other cancer types, we either don’t have enough data yet or...
Latest News
Adverse skin effects of cancer immunotherapy reviewed
“The desirable, immune-mediated oncologic response is often achieved at the cost of immune-related adverse events (irAEs) that may potentially...
Latest News
Untargeted CT scans leads to overdiagnoses in lung cancer
The dangers of overdiagnosis are counterintuitive, but real.
Latest News
Intensity-modulated radiotherapy reduces esophagitis in palliative NSCLC
What’s the balance between tumor coverage and sparing healthy tissue in the palliative setting?
From the Journals
Lung cancer with ILD patients fare poorly after thoracic radiotherapy
News
FDA approves neoadjuvant nivolumab/chemo for early-stage NSCLC
Nivolumab is the first immune checkpoint inhibitor to be approved for resectable NSCLC.